REFERENCES
2. Xue C, Senchanthisai S, Sowden M, Pang J, White RJ, Berk BC. Endothelial-to-mesenchymal transition and inflammation play key roles in cyclophilin A-induced pulmonary arterial hypertension. Hypertension. 2020;76:1113-23.
3. Zhao H, Song J, Li X, et al. The role of immune cells and inflammation in pulmonary hypertension: mechanisms and implications. Front Immunol. 2024;15:1374506.
4. Chen T, Lin X, Lu S, Li B. V-ATPase in cancer: mechanistic insights and therapeutic potentials. Cell Commun Signal. 2024;22:613.
5. Cao M, Luo X, Wu K, He X. Targeting lysosomes in human disease: from basic research to clinical applications. Signal Transduct Target Ther. 2021;6:379.
7. Recla S, Hahn A, Apitz C. Pulmonary arterial hypertension associated with impaired lysosomal endothelin-1 degradation. Cardiol Young. 2015;25:773-6.
8. Castroflorio E, den Hoed J, Svistunova D, et al. The Ncoa7 locus regulates V-ATPase formation and function, neurodevelopment and behaviour. Cell Mol Life Sci. 2021;78:3503-24.
9. Doyle T, Moncorgé O, Bonaventure B, et al. The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry. Nat Microbiol. 2018;3:1369-76.
10. Harvey LD, Alotaibi M, Tai YY, et al. Lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension. Science. 2025;387:eadn7277.
11. Griffiths WJ, Wang Y. Oxysterols as lipid mediators: their biosynthetic genes, enzymes and metabolites. Prostaglandins Other Lipid Mediat. 2020;147:106381.
12. Canfrán-Duque A, Rotllan N, Zhang X, et al. Macrophage-derived 25-hydroxycholesterol promotes vascular inflammation, atherogenesis, and lesion remodeling. Circulation. 2023;147:388-408.
13. Boucherat O, Agrawal V, Lawrie A, Bonnet S. The latest in animal models of pulmonary hypertension and right ventricular failure. Circ Res. 2022;130:1466-86.
14. Xu D, Hu YH, Gou X, et al. Oxidative stress and antioxidative therapy in pulmonary arterial hypertension. Molecules. 2022:27.
15. Ruiz F, Peter B, Rebeaud J, et al. Endothelial cell-derived oxysterol ablation attenuates experimental autoimmune encephalomyelitis. EMBO Rep. 2023;24:e55328.
